Virtual Meeting to be held on September 24 hosted by Piper Sandler.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Promising Long-Term Efficacy and Safety of ALXN1840 Strengthens Buy Rating for Monopar Therapeutics Inc.
- Monopar Therapeutics Presents New Data on ALXN1840
- Monopar Therapeutics Inc’s ALXN1840: A Promising Breakthrough in Wilson Disease Treatment Justifying Buy Rating
- Monopar Therapeutics announces new data from study of ALXN1840
- Monopar Therapeutics initiated with a Buy at BTIG